[Progress in the molecular analysis of infant leukemias].
Ishii
Eiichi
E
D004791:Enzyme Inhibitors / Q000009:adverse effects; D005047:Etoposide / Q000009:adverse effects*; D005260:Female; D015321:Gene Rearrangement; D020022:Genetic Predisposition to Disease; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000235:genetics*; D008297:Male; D018811:Maternal Exposure / Q000009:adverse effects; D035683:MicroRNAs; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics*; D011247:Pregnancy; D059005:Topoisomerase II Inhibitors
D004791:Enzyme Inhibitors; C497422:KMT2A protein, human; D035683:MicroRNAs; D059005:Topoisomerase II Inhibitors; D051788:Myeloid-Lymphoid Leukemia Protein; D005047:Etoposide; D011495:Histone-Lysine N-Methyltransferase